Filing Flows › Taysha Gene Therapies (TSHA) › Q2 2025
Taysha Gene Therapies (TSHA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Taysha Gene Therapies (TSHA) reported revenue of $2.0M for the second quarter 2025 (Q2 2025), +79% from a year earlier and -14% from the quarter before.
Taysha Gene Therapies, Q2 2025: revenue $2.0M (+79% year over year), net loss $26.9M, operating cash flow −$20.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.0M | -14% | +79% |
| Operating profit | −$26.8M | — | — |
| Net earnings | −$26.9M | — | — |
| Operating cash flow | −$20.2M | — | — |
What changed
Revenue was $2.0M in Q2 2025, up 79% year over year and down 14% from the previous quarter.
Operating costs exceeded revenue by $26.8M, an operating margin of -1347.1%. Total costs grew 28% against revenue growth of 79%. The fastest-growing cost line was Research & development (+34%). The quarter ended with a net loss of $26.9M, wider than the previous quarter's $21.5M loss.
Operating cash flow was −$20.2M. Non-cash charges added back $300K of depreciation and $3.2M of share-based compensation. Working capital and other items added $3.2M. Capital expenditures of $2K exceeded it, leaving free cash flow of −$20.2M.
Questions
What was Taysha Gene Therapies' revenue in the second quarter 2025?
Taysha Gene Therapies (TSHA) reported revenue of $2.0M for the second quarter 2025 (Q2 2025), +79% from a year earlier and -14% from the quarter before.